IL1R1 and inflammatory bowel disease: Additionally, ESM-iBET efficiently downregulated oncostatin M (OSM), IL1α, and IL1R,1 which were previously reported to be involved in anti-TNF therapy non-responsiveness [54,55,56] in IBD.